Baillie Gifford & Co
LYEL icon

Baillie Gifford & Co’s Lyell Immunopharma LYEL Stock Holding History

Baillie Gifford & Co’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,097
Closed -$196K – 279
2024
Q3 		$196K Sell
7,097
-18,903
-73% -$555K ﹤0.01% 264
2024
Q2 		$754K Sell
26,000
-6,808
-21% -$324K ﹤0.01% 260
2024
Q1 		$1.46M Sell
32,808
-1,736
-5% -$74.3K ﹤0.01% 252
2023
Q4 		$1.34M Sell
34,544
-2,088
-6% -$75.2K ﹤0.01% 256
2023
Q3 		$1.08M Sell
36,632
-1,434
-4% -$68.1K ﹤0.01% 263
2023
Q2 		$2.42M Hold
38,066
– – ﹤0.01% 251
2023
Q1 		$1.8M Hold
38,066
– – ﹤0.01% 256
2022
Q4 		$2.64M Buy
38,066
+311
+0.8% +$30.9K ﹤0.01% 257
2022
Q3 		$5.54M Buy
37,755
+2,372
+7% +$321K 0.01% 236
2022
Q2 		$4.62M Sell
35,383
-3,854
-10% -$394K ﹤0.01% 237
2022
Q1 		$3.96M Buy
39,237
+3,068
+8% +$372K ﹤0.01% 256
2021
Q4 		$5.6M Buy
36,169
+14,795
+69% +$3.3M ﹤0.01% 260
2021
Q3 		$6.33M Buy
21,374
+8,433
+65% +$2.53M ﹤0.01% 256
2021
Q2 		$4.2M Buy
+12,941
New +$4.24M ﹤0.01% 260

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Baillie Gifford & Co's LYEL Position: Q4 2024 in Review

Baillie Gifford & Co sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 7,097 shares — an estimated $196K sold.

Baillie Gifford & Co first reported a position in LYEL in Q2 2021 and held it in 14 quarters. The position peaked at $6.33M in Q3 2021. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Baillie Gifford & Co reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Baillie Gifford & Co sold 7,097 Lyell Immunopharma shares in Q4 2024, an estimated $196K.
  • Baillie Gifford & Co first reported a position in Lyell Immunopharma in Q2 2021 and held it in 14 quarters.
  • Baillie Gifford & Co's Lyell Immunopharma position peaked at $6.33M in Q3 2021.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Baillie Gifford & Co's 13F filing for Q4 2024, filed 31 Jan 2025.